CTNNB1 and Cirrhosis: Remaining 46 patients lacked any genetic alterations in exon-3 of CTNNB1. Additionally, we enrolled healthy volunteers and also patients with cirrhosis due to chronic liver disease (Table 3) to determine serum LECT2 levels and address its efficacy as a tumor marker.